English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 30 April 2024, 18:00 JST
Share:
    

Source: BioMed X Institute
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who can benefit from cancer immunotherapy.

HEIDELBERG, Germany, Apr 30, 2024 - (ACN Newswire) - BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany. The main objective of the project is to develop novel immunotherapeutic strategies to overcome the immunosuppressive microenvironment of solid tumors.

Independent of tumor indication, the general immunogenicity of a tumor is positively correlated with a better prognosis and a more robust response to immune checkpoint blockade. The current paradigm envisions tumor mutations as one of the sources of immunogenic neoantigens, which are expressed and presented on the surface of the tumor cells and recognized by the immune system to mount an effective anti-tumor response. The main objective of this research group is to identify how the DNA damage response (DDR) can be harnessed to increase the immunogenicity of tumor cells. The final goal is to design novel therapeutic approaches that promote a favorable tumor microenvironment for immunotherapies.

Dr. Semih Akincilar, the scientist leading this project, explains: "Using colorectal cancer as a model, we will investigate the molecular pathways altered in immunogenic and non-immunogenic tumor clusters. This will help us to better understand the links between DNA damage response and tumor immunogenicity, with significant implications for oncological treatment."

The BioMed X Institute and Merck have been collaborating since 2013, partnering on both oncology and immunology research projects, with the end goal of developing new therapies for cancer and autoimmune diseases. "With our most recent projects in collaboration with Merck and others, we are deepening our expertise in tumor immunology," said Christian Tidona, Founder and Managing Director of the BioMed X Institute. Further details about this project can be found on the BioMed X Institute website (www.bio.mx).

About BioMed X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706

SOURCE: BioMed X Institute

.

View the original press release on newswire.com.



Topic: Press release summary
Source: BioMed X Institute

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

BioMed X Institute Related News
May 28, 2024 18:00 HKT/SGT
BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project
May 16, 2024 22:00 HKT/SGT
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
Feb 6, 2024 23:00 HKT/SGT
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
Dec 22, 2023 09:00 HKT/SGT
BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research
Dec 22, 2023 09:00 HKT/SGT
BioMed X 研究所与小野药品公司(Ono Pharmaceutical)在癌症研究领域启动新的合作
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575